AustraliaHealth

PYC Therapeutics (ASX:PYC) has launched a "monster" $653 million equity raising aimed at propelling its rare genetic disease portfolio through 2030.

Memphasys (ASX:MEM) announced a breakthrough in its Middle East expansion, securing its first major institutional reference customer in the region.

Synthetic anti-infectives biotech Recce Pharmaceuticals (ASX:RCE) has entered into a Cooperative Research and Development Agreement with the US Army Institute of Surgical Research.

OncoSil Medical (ASX:OSL) announced early clinical results from Ankara Bilkent City Hospital in Türkiye, demonstrating a potential paradigm shift in the treatment of unresectable locally advanced pancreatic cancer.

Atomo Diagnostics (ASX:AT1) announced a new purchase order valued at $416,000 for its HIV Self-Tests, destined for a major health initiative in Africa.

ResMed's (ASX:RMD) revenue for the second quarter to December 2025 climbed 11% to $1.4 billion, reflecting a 9% increase on a constant currency basis.

Mayne Pharma (ASX:MYX) is set to return to the Supreme Court of New South Wales next month to recover legal costs from its failed $672 million takeover by US-based Cosette Pharmaceuticals.

Imricor Medical Systems (ASX:IMR) has achieved a major regulatory milestone with the US Food and Drug Administration granting 510(k) clearance for its NorthStar Mapping System.

Clinical-stage biopharmaceutical leader Radiopharm Theranostics (ASX:RAD) has released its financial results for the first half of fiscal 2026, reporting a cash position of $34.5 million and a series of significant clinical breakthroughs.

Rhythm Biosciences (ASX:RHY) has secured a strategic partnership with CancerIQ, a US digital oncology platform.

Mesoblast (ASX:MSB) reported encouraging real-world outcomes for its FDA-approved therapy Ryoncil (remestemcel-L-rknd) in children with steroid-refractory acute graft-versus-host disease.

Monash IVF Group (ASX:MVF) announced the resignation of its CFO and company secretary, Malik Jainudeen.